0000899243-21-016272.txt : 20210419
0000899243-21-016272.hdr.sgml : 20210419
20210419191216
ACCESSION NUMBER: 0000899243-21-016272
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210415
FILED AS OF DATE: 20210419
DATE AS OF CHANGE: 20210419
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mainolfi Nello
CENTRAL INDEX KEY: 0001821189
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39460
FILM NUMBER: 21835846
MAIL ADDRESS:
STREET 1: C/O KYMERA THERAPEUTICS, INC.
STREET 2: 200 ARSENAL YARDS, SUITE 230
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kymera Therapeutics, Inc.
CENTRAL INDEX KEY: 0001815442
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 812992166
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 TECHNOLOGY SQUARE
STREET 2: 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-285-5314
MAIL ADDRESS:
STREET 1: 300 TECHNOLOGY SQUARE
STREET 2: 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-04-15
0
0001815442
Kymera Therapeutics, Inc.
KYMR
0001821189
Mainolfi Nello
C/O KYMERA THERAPEUTICS, INC.
200 ARSENAL YARDS BLVD., SUITE 230
WATERTOWN
MA
02472
1
1
0
0
Chief Executive Officer
Common Stock
2021-04-15
4
M
0
4940
2.08
A
396139
D
Common Stock
2021-04-15
4
S
0
4940
40.2912
D
391199
D
Common Stock
2021-04-19
4
M
0
653
2.08
A
391852
D
Common Stock
2021-04-19
4
S
0
653
40.001
D
391199
D
Common Stock
2021-04-19
4
M
0
6000
2.08
A
397199
D
Stock Option (Right to Buy)
2.08
2021-04-15
4
M
0
4940
0.00
D
2029-11-13
Common Stock
4940
239785
D
Stock Option (Right to Buy)
2.08
2021-04-19
4
M
0
653
0.00
D
2029-11-13
Common Stock
653
239132
D
Stock Option (Right to Buy)
2.08
2021-04-19
4
M
0
6000
0.00
D
2029-05-22
Common Stock
6000
151424
D
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.
The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.
/s/ Bruce Jacobs, as Attorney-in-Fact
2021-04-19